Amgen Inc. (AMGN) Holdings Reduced by Clear Harbor Asset Management LLC

Clear Harbor Asset Management LLC cut its position in Amgen Inc. (NASDAQ:AMGN) by 2.2% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 6,149 shares of the medical research company’s stock after selling 136 shares during the period. Clear Harbor Asset Management LLC’s holdings in Amgen were worth $1,065,000 at the end of the most recent quarter.

Several other hedge funds have also recently made changes to their positions in the company. Jackson Grant Investment Advisers Inc. grew its holdings in Amgen by 0.6% during the first quarter. Jackson Grant Investment Advisers Inc. now owns 636 shares of the medical research company’s stock worth $104,000 after acquiring an additional 4 shares during the period. Investment Partners Ltd. OH ADV grew its holdings in Amgen by 0.5% during the second quarter. Investment Partners Ltd. OH ADV now owns 2,192 shares of the medical research company’s stock worth $377,000 after acquiring an additional 11 shares during the period. Conservest Capital Advisors Inc. grew its holdings in Amgen by 0.4% during the second quarter. Conservest Capital Advisors Inc. now owns 3,130 shares of the medical research company’s stock worth $539,000 after acquiring an additional 13 shares during the period. Arvest Bank Trust Division grew its holdings in Amgen by 0.9% during the second quarter. Arvest Bank Trust Division now owns 1,508 shares of the medical research company’s stock worth $260,000 after acquiring an additional 13 shares during the period. Finally, First Command Financial Services Inc. grew its holdings in Amgen by 1.1% during the first quarter. First Command Financial Services Inc. now owns 1,547 shares of the medical research company’s stock worth $254,000 after acquiring an additional 17 shares during the period. 78.09% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: This piece was posted by BBNS and is the property of of BBNS. If you are accessing this piece on another publication, it was illegally copied and republished in violation of United States & international copyright and trademark law. The legal version of this piece can be accessed at https://baseballnewssource.com/markets/clear-harbor-asset-management-llc-sells-136-shares-of-amgen-inc-amgn/1605312.html.

AMGN has been the topic of several analyst reports. Cann reaffirmed a “buy” rating on shares of Amgen in a report on Monday, August 28th. Oppenheimer Holdings, Inc. reiterated a “buy” rating and set a $203.00 price target on shares of Amgen in a research report on Thursday, September 7th. Deutsche Bank AG started coverage on Amgen in a research report on Friday, June 23rd. They set a “hold” rating and a $172.00 price target on the stock. ValuEngine downgraded Amgen from a “buy” rating to a “hold” rating in a research report on Friday, June 2nd. Finally, William Blair reiterated a “market perform” rating on shares of Amgen in a research report on Monday, June 26th. One analyst has rated the stock with a sell rating, twelve have given a hold rating, eleven have issued a buy rating and two have given a strong buy rating to the stock. Amgen presently has a consensus rating of “Buy” and a consensus target price of $186.14.

Amgen Inc. (AMGN) opened at 185.76 on Friday. The firm has a market capitalization of $135.54 billion, a PE ratio of 16.92 and a beta of 1.35. The company’s 50-day moving average price is $175.99 and its 200 day moving average price is $169.31. Amgen Inc. has a 1-year low of $133.64 and a 1-year high of $191.10.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Tuesday, July 25th. The medical research company reported $3.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.11 by $0.16. The business had revenue of $5.81 billion during the quarter, compared to analyst estimates of $5.67 billion. Amgen had a net margin of 35.46% and a return on equity of 29.85%. Amgen’s quarterly revenue was up 2.1% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.84 EPS. On average, equities analysts anticipate that Amgen Inc. will post $12.57 EPS for the current year.

The company also recently announced a quarterly dividend, which was paid on Friday, September 8th. Shareholders of record on Thursday, August 17th were given a dividend of $1.15 per share. This represents a $4.60 dividend on an annualized basis and a yield of 2.48%. The ex-dividend date of this dividend was Tuesday, August 15th. Amgen’s dividend payout ratio is 41.93%.

Amgen Profile

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with our FREE daily email newsletter.

 


Latest News

American League Once Again Dominates National League
American League Once Again Dominates National League
Los Angeles Dodgers Waiting But Magic Number Down to One
Los Angeles Dodgers Waiting But Magic Number Down to One
Young Girl Hit by Foul Ball Rushed to Hospital
Young Girl Hit by Foul Ball Rushed to Hospital
New Home Run Record Reached in Major League Baseball
New Home Run Record Reached in Major League Baseball
Will 2017 MLB Season End with No 20-Game Winner?
Will 2017 MLB Season End with No 20-Game Winner?
Cleveland Indians Winning Streak Snapped at 22
Cleveland Indians Winning Streak Snapped at 22


Leave a Reply

 
© 2006-2017 BBNS.